Evidence map›Paper›PMID 34389561›Full record

ArticleBMJ open2021

Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.

Yeri Lee, Ahhyung Choi, Yunha Noh, Ha-Lim Jeon, Seung-Ah Choe, Ju-Young Shin

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yeri Lee *School of Pharmacy, Sungkyunkwan University, Suwon, Korea (the Republic of).
Ahhyung Choi *School of Pharmacy, Sungkyunkwan University, Suwon, Korea (the Republic of).
Yunha NohSchool of Pharmacy, Sungkyunkwan University, Suwon, Korea (the Republic of).
Ha-Lim JeonSchool of Pharmacy, Sungkyunkwan University, Suwon, Korea (the Republic of).
Seung-Ah ChoeDepartment of Preventive Medicine, College of Medicine, Korea University, Seoul, Korea (the Republic of).ORCID 0000-0001-6270-5020
Ju-Young ShinSchool of Pharmacy, Sungkyunkwan University, Suwon, Korea (the Republic of) shin.jy@skku.edu.ORCID 0000-0003-1010-7525
Sungkyunkwan University · KRKorea University · KRSamsung (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting pattern of adverse events (AEs) caused by DCOCs compared with levonorgestrel/desogestrel/gestodene-containing (second/third generation) oral contraceptives.

designA descriptive analysis of claims data.

settingThe Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database from 1 February 2008 to 31 December 2017. OUTCOME MEASURES: Signals for DCOCs were identified using three data mining indices. The characteristics, death cases, and the annual pattern of AE reports were compared between DCOCs and second/third generation oral contraceptives.

resultsOf the 242 DCOC-related AEs, 54 signals were detected and 10 were identified as new signals that were not included in Korea, US and UK label. The newly detected signals include deep vein thrombophlebitis and frequent urination. Serious AEs were more likely to be reported with DCOCs (7.85%) than with second/third generation oral contraceptives (2.92%). Five deaths after use of DCOCs were reported with vascular AEs, such as pulmonary embolism and thrombosis, whereas one death after use of second/third generation oral contraceptives was reported with the cardiac arrest.

conclusionsWe identified 10 new signals related to DCOCs that were not included in the current label. Additionally, we found higher reports of the deaths and vascular AEs associated with DCOCs than with second/third generation oral contraceptives, which warrants careful monitoring to ensure the safe use of DCOCs.

Indexed as

Contraceptives, OralDesogestrelAndrostenesFemaleHumansRepublic of KoreaRisk FactorsAndrostenesContraceptives, OralDesogestreldrospirenoneadverse eventsepidemiologygynaecology

Identifiers

PMID34389561
PMCPMC8365811
OpenAlexW3192995439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.